- Home
- LVO vs ACET Comparison
LVO vs ACET Comparison
Compare LVO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- ACET
- Stock Information
- Founded
- LVO 2009
- ACET 1947
- Country
- LVO United States
- ACET United States
- Employees
- LVO N/A
- ACET N/A
- Industry
- LVO Restaurants
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- LVO Consumer Discretionary
- ACET Health Care
- Exchange
- LVO Nasdaq
- ACET Nasdaq
- Market Cap
- LVO 68.1M
- ACET 63.5M
- IPO Year
- LVO N/A
- ACET N/A
- Fundamental
- Price
- LVO $0.48
- ACET $0.76
- Analyst Decision
- LVO Strong Buy
- ACET Buy
- Analyst Count
- LVO 2
- ACET 5
- Target Price
- LVO $1.40
- ACET $5.33
- AVG Volume (30 Days)
- LVO 849.4K
- ACET 463.1K
- Earning Date
- LVO 11-06-2025
- ACET 11-05-2025
- Dividend Yield
- LVO N/A
- ACET N/A
- EPS Growth
- LVO N/A
- ACET N/A
- EPS
- LVO N/A
- ACET N/A
- Revenue
- LVO $100,534,000.00
- ACET N/A
- Revenue This Year
- LVO N/A
- ACET N/A
- Revenue Next Year
- LVO $24.07
- ACET N/A
- P/E Ratio
- LVO N/A
- ACET N/A
- Revenue Growth
- LVO N/A
- ACET N/A
- 52 Week Low
- LVO $0.43
- ACET $0.45
- 52 Week High
- LVO $1.60
- ACET $1.57
- Technical
- Relative Strength Index (RSI)
- LVO 38.77
- ACET 51.10
- Support Level
- LVO $0.52
- ACET $0.77
- Resistance Level
- LVO $0.59
- ACET $0.84
- Average True Range (ATR)
- LVO 0.05
- ACET 0.06
- MACD
- LVO 0.01
- ACET 0.00
- Stochastic Oscillator
- LVO 27.94
- ACET 33.91
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.